Generics lead the charge in biotech boom


After a record-breaking 2014, 2015 is shaping up to be another momentous year for biotech. During the first few months of 2015 to the beginning of March, the value of M&A deals in the pharma sector hit $59.3bn, up 94% year on year. Over the past four weeks, at least four more multi-billion dollar deals have been announced. Generic drug production is one of the biotech market’s hottest industries. Indeed, as consumers around the world switch to low-cost generic drugs to combat ever-higher medical bills, generic producers have struggled to meet demand. Hikma is one of the companies that has been able to benefit from this trend.

Read the source article at The Motley Fool UK

About the Author

Leave a Reply